Trial Profile
An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs CSL 112 (Primary)
- Indications Acute coronary syndromes; Atherosclerosis
- Focus Adverse reactions; Biomarker
- Sponsors CSL
- 04 Apr 2022 Data from 5 clinical trials (single and multiple ascending dose phase 1 studies in healthy volunteers, a phase 2a study in subjects with stable atherosclerotic disease, a phase 2b study in subjects post-AMI (AEGIS-I), and a phase 1 Japanese ethno-bridging study) assessing pharmacokinetics (PK) and pharmacodynamics (PD) of CSL112 across different populations, presented at the 71st Annual Scientific Session of the American College of Cardiology.
- 20 Nov 2020 Results of pharmacometric analyses characterizing the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients published in the British Journal of Clinical Pharmacology
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.